CL2017001943A1 - Terapias de combinación para el tratamiento de cánceres - Google Patents
Terapias de combinación para el tratamiento de cánceresInfo
- Publication number
- CL2017001943A1 CL2017001943A1 CL2017001943A CL2017001943A CL2017001943A1 CL 2017001943 A1 CL2017001943 A1 CL 2017001943A1 CL 2017001943 A CL2017001943 A CL 2017001943A CL 2017001943 A CL2017001943 A CL 2017001943A CL 2017001943 A1 CL2017001943 A1 CL 2017001943A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- cancers
- combination therapies
- malignities
- entospletinib
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 abstract 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 abstract 1
- 239000012664 BCL-2-inhibitor Substances 0.000 abstract 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229950004136 entospletinib Drugs 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 229950004847 navitoclax Drugs 0.000 abstract 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001183 venetoclax Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>SE PROPORCIONAN EN EL PRESENTE DOCUMENTO MÉTODOS QUE SE RELACIONAN CON UNA ESTRATEGIA TERAPÉUTICA PARA EL TRATAMIENTO DEL CÁNCER, INCLUYENDO MALIGNIDADES HEMATOLÓGICAS. EN PARTICULAR, LOS MÉTODOS INCLUYEN LA ADMINISTRACIÓN DE ENTOSPLETINIB Y UN INHIBIDOR DE BCL-2, TAL COMO VENETOCLAX, NAVITOCLAX Y ABT-737.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111604P | 2015-02-03 | 2015-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017001943A1 true CL2017001943A1 (es) | 2018-03-02 |
Family
ID=55398445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001943A CL2017001943A1 (es) | 2015-02-03 | 2017-07-28 | Terapias de combinación para el tratamiento de cánceres |
Country Status (25)
Country | Link |
---|---|
US (2) | US20160220573A1 (es) |
EP (1) | EP3253385A1 (es) |
JP (1) | JP2018503653A (es) |
KR (1) | KR20170104616A (es) |
CN (1) | CN107205992A (es) |
AU (1) | AU2016215643A1 (es) |
BR (1) | BR112017016019A2 (es) |
CA (1) | CA2974828A1 (es) |
CL (1) | CL2017001943A1 (es) |
CO (1) | CO2017007662A2 (es) |
CR (1) | CR20170352A (es) |
CU (1) | CU20170099A7 (es) |
EA (1) | EA201791516A1 (es) |
EC (1) | ECSP17048849A (es) |
GT (1) | GT201700167A (es) |
IL (1) | IL253573A0 (es) |
MA (1) | MA41449A (es) |
MD (1) | MD20170073A2 (es) |
MX (1) | MX2017009724A (es) |
PE (1) | PE20171241A1 (es) |
PH (1) | PH12017550063A1 (es) |
SG (1) | SG11201706107SA (es) |
SV (1) | SV2017005489A (es) |
TW (1) | TW201639573A (es) |
WO (1) | WO2016126552A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5696052B2 (ja) | 2008-12-08 | 2015-04-08 | ギリアード コネチカット, インコーポレイテッド | イミダゾピラジンsyk阻害剤 |
US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
BR112016001954A2 (pt) | 2013-07-31 | 2017-08-01 | Gilead Sciences Inc | composto, composição farmacêutica, e, método para tratar uma doença ou condição |
PT3076976T (pt) | 2013-12-04 | 2020-12-07 | Kronos Bio Inc | Métodos para tratar cancros |
TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
AU2015290000B2 (en) | 2014-07-14 | 2018-05-17 | Gilead Sciences, Inc. | Combinations for treating cancers |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US10759798B2 (en) * | 2016-09-14 | 2020-09-01 | Hangzhou Solipharma Co., Ltd. | ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof |
CA3036384A1 (en) | 2016-09-14 | 2018-03-22 | Gilead Sciences, Inc. | Syk inhibitors |
EP3615047A4 (en) * | 2017-04-28 | 2021-01-13 | Actinium Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER USING A BCL-2 INHIBITOR IN COMBINATION WITH ALPHA EMISSION RADIOIMMUNOTHERAPY |
WO2019040298A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | SYK INHIBITORY POLYMORPHS |
KR20200108302A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
MX2021010131A (es) | 2019-02-22 | 2021-11-18 | Kronos Bio Inc | Formas sólidas de pirazinas condensadas a manera de inhibidores de syk. |
CA3142361A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
EP4069233A4 (en) * | 2019-12-04 | 2024-03-13 | Ascentage Pharma Suzhou Co Ltd | PHARMACEUTICAL COMBINATION AND USE THEREOF |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
CA3214527A1 (en) * | 2021-04-05 | 2022-10-13 | Doo-Young Jung | Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
KR101509440B1 (ko) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
KR20170013414A (ko) * | 2008-12-08 | 2017-02-06 | 질레드 코네티컷 인코포레이티드 | 이미다조피라진 syk 억제제 |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
WO2011034934A1 (en) | 2009-09-20 | 2011-03-24 | Abbott Laboratories | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
SG183174A1 (en) | 2010-02-04 | 2012-09-27 | Gilead Biologics Inc | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
JP5878538B2 (ja) | 2010-08-27 | 2016-03-08 | ギリアド バイオロジクス, インク.Gilead Biologics, Inc. | マトリクスメタロプロティナーゼ9に対する抗体 |
NZ610151A (en) | 2010-11-23 | 2015-06-26 | Abbvie Inc | Salts and crystalline forms of an apoptosis-inducing agent |
EP2749572A4 (en) | 2011-08-23 | 2015-04-01 | Chugai Pharmaceutical Co Ltd | NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
US20140235643A1 (en) | 2011-10-04 | 2014-08-21 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
CA2882134A1 (en) * | 2012-08-14 | 2014-02-20 | Gilead Calistoga Llc | Combination therapies for treating cancer |
US9539251B2 (en) * | 2012-09-07 | 2017-01-10 | Genentech, Inc. | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
WO2014047624A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
US9029384B2 (en) | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
NZ708864A (en) | 2012-12-21 | 2016-09-30 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
WO2014201409A1 (en) | 2013-06-14 | 2014-12-18 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
NZ715776A (en) | 2013-07-30 | 2017-04-28 | Gilead Connecticut Inc | Polymorph of syk inhibitors |
PE20160605A1 (es) | 2013-07-30 | 2016-07-20 | Gilead Connecticut Inc | Formulaciones de inhibidores de la syk |
EP2886146A1 (en) * | 2013-12-20 | 2015-06-24 | Sanofi-Aventis Deutschland GmbH | Needle safety device and drug delivery device |
-
2016
- 2016-01-21 TW TW105101876A patent/TW201639573A/zh unknown
- 2016-01-28 MA MA041449A patent/MA41449A/fr unknown
- 2016-01-29 CR CR20170352A patent/CR20170352A/es unknown
- 2016-01-29 EA EA201791516A patent/EA201791516A1/ru unknown
- 2016-01-29 MX MX2017009724A patent/MX2017009724A/es unknown
- 2016-01-29 SG SG11201706107SA patent/SG11201706107SA/en unknown
- 2016-01-29 CN CN201680007860.5A patent/CN107205992A/zh active Pending
- 2016-01-29 BR BR112017016019A patent/BR112017016019A2/pt not_active Application Discontinuation
- 2016-01-29 US US15/010,906 patent/US20160220573A1/en not_active Abandoned
- 2016-01-29 JP JP2017539623A patent/JP2018503653A/ja active Pending
- 2016-01-29 KR KR1020177023454A patent/KR20170104616A/ko not_active Application Discontinuation
- 2016-01-29 WO PCT/US2016/015727 patent/WO2016126552A1/en active Application Filing
- 2016-01-29 EP EP16705384.2A patent/EP3253385A1/en not_active Withdrawn
- 2016-01-29 PE PE2017001282A patent/PE20171241A1/es not_active Application Discontinuation
- 2016-01-29 US US15/548,401 patent/US20180117052A1/en not_active Abandoned
- 2016-01-29 CA CA2974828A patent/CA2974828A1/en not_active Abandoned
- 2016-01-29 MD MDA20170073A patent/MD20170073A2/ro not_active Application Discontinuation
- 2016-01-29 AU AU2016215643A patent/AU2016215643A1/en not_active Abandoned
- 2016-01-29 CU CUP2017000099A patent/CU20170099A7/es unknown
-
2017
- 2017-07-19 IL IL253573A patent/IL253573A0/en unknown
- 2017-07-27 GT GT201700167A patent/GT201700167A/es unknown
- 2017-07-28 CL CL2017001943A patent/CL2017001943A1/es unknown
- 2017-07-28 EC ECIEPI201748849A patent/ECSP17048849A/es unknown
- 2017-07-28 CO CONC2017/0007662A patent/CO2017007662A2/es unknown
- 2017-07-28 SV SV2017005489A patent/SV2017005489A/es unknown
- 2017-07-31 PH PH12017550063A patent/PH12017550063A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP17048849A (es) | 2017-10-31 |
IL253573A0 (en) | 2017-09-28 |
PH12017550063A1 (en) | 2018-02-05 |
BR112017016019A2 (pt) | 2018-03-20 |
US20160220573A1 (en) | 2016-08-04 |
MA41449A (fr) | 2017-12-12 |
SV2017005489A (es) | 2017-10-17 |
CR20170352A (es) | 2017-09-29 |
EP3253385A1 (en) | 2017-12-13 |
MD20170073A2 (ro) | 2018-02-28 |
PE20171241A1 (es) | 2017-08-24 |
US20180117052A1 (en) | 2018-05-03 |
MX2017009724A (es) | 2017-11-17 |
CN107205992A (zh) | 2017-09-26 |
GT201700167A (es) | 2017-11-02 |
EA201791516A1 (ru) | 2018-01-31 |
CO2017007662A2 (es) | 2017-10-20 |
JP2018503653A (ja) | 2018-02-08 |
SG11201706107SA (en) | 2017-08-30 |
WO2016126552A1 (en) | 2016-08-11 |
CU20170099A7 (es) | 2018-03-13 |
TW201639573A (zh) | 2016-11-16 |
AU2016215643A1 (en) | 2017-08-10 |
CA2974828A1 (en) | 2016-08-11 |
KR20170104616A (ko) | 2017-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001943A1 (es) | Terapias de combinación para el tratamiento de cánceres | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
CR20150316A (es) | Compuestos y sus métodos de empleo | |
UY36075A (es) | Derivados de tubulisina | |
CL2018000222A1 (es) | Nueva combinación para el uso en el tratamiento del cáncer | |
ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
CL2016003260A1 (es) | Profármacos de gemcitabina | |
CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CL2017000391A1 (es) | Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
GT201400071A (es) | Combinación terapéutica para el tratamiento de cáncer | |
UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek |